Cat. No.: DAA-001284
Product Information | |
---|---|
Product Name | Human Resistin ELISA Kit |
Species | Human |
Description | Human Resistin ELISA kit is a single-wash 90 min sandwich ELISA designed for the quantitative measurement of Resistin protein in human serum, plasma and cell culture supernatants. It uses our proprietary ELISA technology. Quantitate human Resistin with 24 pg/mL sensitivity.ELISA technology employs capture antibodies conjugated to an affinity tag that is recognized by the monoclonal antibody used to coat our ELISA plates. |
Sample Types | Cell Culture Supernatant, Serum, Hep Plasma, Edta Plasma, Cit Plasma |
Detection Range | 78.1 pg/mL - 5000 pg/mL |
Sensitivity | 24 pg/mL |
Target Information | |
---|---|
Target Name | RETN |
UniProt No. | Q9HD89 |
Gene ID | 56729 |
Target Description | Hormone that seems to suppress insulin ability to stimulate glucose uptake into adipose cells. Potentially links obesity to diabetes. |
Alternative Names | Adipose tissue specific secretory factor; Adipose tissue-specific secretory factor; ADSF; C/EBP epsilon regulated myeloid specific secreted cysteine rich protein; C/EBP epsilon regulated myeloid specific secreted cysteine rich protein precursor 1; C/EBP-epsilon-regulated myeloid-specific secreted cysteine-rich protein; CG5403; Cysteine rich secreted protein A12 alpha like 2; Cysteine rich secreted protein FIZZ3; Cysteine-rich secreted protein A12-alpha-like 2; Cysteine-rich secreted protein FIZZ3; dri; FIZZ 3; FIZZ3; Found in inflammatory zone 3; HXCP 1; HXCP1; MGC126603; MGC126609; PRO1199; Resistin; Resistin delta2; RETN; RETN 1; RETN_HUMAN; RETN1; RSTN; UNQ407; XCP 1; XCP1 |
Shipping & Storage | |
---|---|
Sipping | Shipping on dry ice. |
Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.